Skip to main content

Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  

Continue reading